201 related articles for article (PubMed ID: 18462372)
1. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia.
Bogazzi F; Buralli S; Manetti L; Raffaelli V; Cigni T; Lombardi M; Boresi F; Taddei S; Salvetti A; Martino E
Int J Clin Pract; 2008 Dec; 62(12):1864-9. PubMed ID: 18462372
[TBL] [Abstract][Full Text] [Related]
2. No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly.
Maione L; Garcia C; Bouchachi A; Kallel N; Maison P; Salenave S; Young J; Assayag P; Chanson P
J Clin Endocrinol Metab; 2012 Sep; 97(9):E1714-9. PubMed ID: 22723314
[TBL] [Abstract][Full Text] [Related]
3. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Colao A; Galderisi M; Di Sarno A; Pardo M; Gaccione M; D'Andrea M; Guerra E; Pivonello R; Lerro G; Lombardi G
J Clin Endocrinol Metab; 2008 Oct; 93(10):3777-84. PubMed ID: 18682513
[TBL] [Abstract][Full Text] [Related]
4. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
[TBL] [Abstract][Full Text] [Related]
5. No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma.
Halperin I; Aller J; Varela C; Mora M; Abad A; Doltra A; Santos AE; Batista E; García-Pavía P; Sitges M; Mirelis JG; Lucas T; Puig-Domingo M
Clin Endocrinol (Oxf); 2012 Aug; 77(2):275-80. PubMed ID: 22288503
[TBL] [Abstract][Full Text] [Related]
6. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
7. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.
Zanettini R; Antonini A; Gatto G; Gentile R; Tesei S; Pezzoli G
N Engl J Med; 2007 Jan; 356(1):39-46. PubMed ID: 17202454
[TBL] [Abstract][Full Text] [Related]
8. Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas.
Auriemma RS; Pivonello R; Perone Y; Grasso LF; Ferreri L; Simeoli C; Iacuaniello D; Gasperi M; Colao A
Eur J Endocrinol; 2013 Sep; 169(3):359-66. PubMed ID: 23824978
[TBL] [Abstract][Full Text] [Related]
9. Cabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti P; Livadariu E; Markov M; Daly AF; Burlacu MC; Betea D; Pierard L; Beckers A
Eur J Endocrinol; 2008 Jul; 159(1):1-5. PubMed ID: 18456868
[TBL] [Abstract][Full Text] [Related]
10. Dopamine agonists and the risk of cardiac-valve regurgitation.
Schade R; Andersohn F; Suissa S; Haverkamp W; Garbe E
N Engl J Med; 2007 Jan; 356(1):29-38. PubMed ID: 17202453
[TBL] [Abstract][Full Text] [Related]
11. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.
Wakil A; Rigby AS; Clark AL; Kallvikbacka-Bennett A; Atkin SL
Eur J Endocrinol; 2008 Oct; 159(4):R11-4. PubMed ID: 18625690
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
Vallette S; Serri K; Serri O
Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
[TBL] [Abstract][Full Text] [Related]
13. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia.
Tan T; Cabrita IZ; Hensman D; Grogono J; Dhillo WS; Baynes KC; Eliahoo J; Meeran K; Robinson S; Nihoyannopoulos P; Martin NM
Clin Endocrinol (Oxf); 2010 Sep; 73(3):369-74. PubMed ID: 20550538
[TBL] [Abstract][Full Text] [Related]
14. [Cabergoline in hyperprolactinemia and valvular heart disease].
Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
De Vecchis R; Esposito C; Ariano C
Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
[TBL] [Abstract][Full Text] [Related]
16. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
17. The frequency of cardiac valvular regurgitation in Parkinson's disease.
Yamashiro K; Komine-Kobayashi M; Hatano T; Urabe T; Mochizuki H; Hattori N; Iwama Y; Daida H; Sakai M; Nakayama T; Mizuno Y
Mov Disord; 2008 May; 23(7):935-941. PubMed ID: 18398916
[TBL] [Abstract][Full Text] [Related]
18. Cabergoline and mitral regurgitation.
Delgrange E
N Engl J Med; 2006 Jan; 354(4):420; author reply 420. PubMed ID: 16436779
[No Abstract] [Full Text] [Related]
19. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
[TBL] [Abstract][Full Text] [Related]
20. Cardiac valvular abnormalities associated with use and cumulative exposure of cabergoline for hyperprolactinemia: the CATCH study.
Budayr A; Tan TC; Lo JC; Zaroff JG; Tabada GH; Yang J; Go AS
BMC Endocr Disord; 2020 Feb; 20(1):25. PubMed ID: 32075620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
